SCHEMBL3450311

SCHEMBL3450311

Cc1c(Br)cn(C)c(=O)c1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
BCAT2 O15382 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
BRD4 O60885 5/20 0.33
MAP2K1 Q02750 1/20 0.33
BRD9 Q9H8M2 1/20 0.32
POLB P06746 1/20 0.32
RECQL P46063 1/20 0.32
FAAH O00519 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
ABHD12 Q8N2K0 1/20 0.32
TP53 P04637 1/20 0.31
LDHA P00338 1/20 0.31
LDHB P07195 1/20 0.31
NOTUM Q6P988 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16650601 0.77 BRD4 (0.34) BRD4MAP2K1BRD9
SCHEMBL2976076 0.77 TP53 (0.39) L3MBTL1MEN1KMT2ABCAT2LMNA
SCHEMBL1254374 0.76 GPR35 (0.46) GPR35L3MBTL1MEN1KMT2ANOTUM
SCHEMBL17975213 0.75 KMT2A (0.39) GPR35L3MBTL1MEN1KMT2AHPGD
SCHEMBL28326993 0.74 BRD9 (0.35) GPR35L3MBTL1MEN1KMT2ALMNA
SCHEMBL3449664 0.74 MKNK1 (0.39) L3MBTL1MEN1KMT2AFAAHCNR1
SCHEMBL22923875 0.74 KDM4E (0.47) L3MBTL1MEN1KMT2ALMNAHPGD
SCHEMBL31384690 0.73 LDHA (0.38) HPGDBRD4BRD9TP53LDHA
SCHEMBL22990247 0.72 MAP2K1 (0.35) BRD4MAP2K1
SCHEMBL20704658 0.72 BRD4 (0.33) MEN1KMT2ABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD GPR35 1156/4885L3MBTL1 4616/4885MEN1 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.